The purpose of the proposed research is to utilize the feline lentivirus, FIV, as a system for testing strategies aimed at the rational design of antivirals efficacious against lentivirus infections. The similarities between FIV and HIV in life cycle, genomic make-up, and etiology of disease resulting from infection make the cat a particularly relevant model. In addition, the relative economy, safety, and manipulability of the feline system make it much more amenable to detailed testing than any of the primate systems. Studies will center around the characterization of FIV protease (PR) and the sites within FIV that are cleaved by this critical enzyme. Both eucaryotic and procaryotic expression clones will be prepared in order to 1) determine PR cleavage sites; 2) establish a hierarchy of cleavage; 3) assess cleavage rates of the natural and synthetic PRs against native substrates; and 4) monitor the influence of drugs arising from Projects 1-4 on Pr cleavage of natural substrates. The data generated will be used for synthetic substrate preparation in Project 4; drug design by projects 1, 2 and 3; for comparison of cleavage specificities with HIV PR; and to aid in the establishment of consensus rules for retroviral PR cleavage. This project will also be responsible for the preparation of site-directed mutants of PR, based on predicted interactions between enzyme and drug, established in Projects 1-4. We will also carry out all virological aspects of the program, which will involve the in vitro testing of selected drugs for both toxicity and antiviral efficacy. The results of these studies will fulfill the anchor phase of the developmental loop, providing support and feedback for design strategies arising from the overall program.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM048870-05
Application #
5212224
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Morris, Garrett M; Green, Luke G; Radi?, Zoran et al. (2013) Automated docking with protein flexibility in the design of femtomolar ""click chemistry"" inhibitors of acetylcholinesterase. J Chem Inf Model 53:898-906
Breuer, Sebastian; Sepulveda, Homero; Chen, Yu et al. (2011) A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry 50:4371-81
Chang, Max W; Torbett, Bruce E (2011) Accessory mutations maintain stability in drug-resistant HIV-1 protease. J Mol Biol 410:756-60
Chang, Max W; Giffin, Michael J; Muller, Rolf et al. (2010) Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem J 429:527-32
Chang, Max W; Ayeni, Christian; Breuer, Sebastian et al. (2010) Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PLoS One 5:e11955
Nelson, Josh D; Kinkead, Heather; Brunel, Florence M et al. (2008) Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377:170-83
Giffin, Michael J; Heaslet, Holly; Brik, Ashraf et al. (2008) A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J Med Chem 51:6263-70
Sundstrom, Magnus; Chatterji, Udayan; Schaffer, Lana et al. (2008) Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins. Virology 371:394-404
Huey, Ruth; Morris, Garrett M; Olson, Arthur J et al. (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28:1145-52
Heaslet, Holly; Rosenfeld, Robin; Giffin, Mike et al. (2007) Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr D Biol Crystallogr 63:866-75

Showing the most recent 10 out of 60 publications